AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27117860 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior shoulder delivery
Number of subjects: 543
Study 27117860 — intervention group
Group type: COMPARATOR
Intervention: Anterior shoulder delivery
Number of subjects: 543
Study 25302456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL 1% lignocaine PPNB and 100 mg diclofenac suppository
Number of subjects: 96
Study 25302456 — intervention group
Group type: COMPARATOR
Intervention: 10 mL 1% lignocaine PPNB and placebo suppository
Number of subjects: 96
Study 21733663 — intervention group
Group type: EXPERIMENTAL
Intervention: citalopram 40 mg/lecozotan 10 mg
Number of subjects: 43
Study 21733663 — intervention group
Group type: COMPARATOR
Intervention: citalopram 40 mg/placebo
Number of subjects: 43
Study 19363437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/d
Number of subjects: 51
Study 17244282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 40 mg
Number of subjects: 261
Study 17244282 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG) 120 mg
Number of subjects: 261
Study 17244282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC)
Number of subjects: 261
Study 17244282 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Number of subjects: 261
Study 17244282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG)
Number of subjects: 261
Study 15838439 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of daily patching with near activities
Number of subjects: 64
Study 15838439 — intervention group
Group type: COMPARATOR
Intervention: 2 hours of daily patching without near activities
Number of subjects: 64
Study 12206590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 65
Study 12206590 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (GT)
Number of subjects: 65
Study 12206590 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual systematic desensitization (SD)
Number of subjects: 65
Study 12206590 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no specialist treatment)
Number of subjects: 65
Study 12206590 — intervention group
Group type: COMPARATOR
Intervention: Control subgroup (observation for 3 years)
Number of subjects: 65
Study 10498596 — intervention group
Group type: EXPERIMENTAL
Intervention: GI5402 (100 mg)
Number of subjects: 7
Study 10498596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8951261 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1-infected children
Number of subjects: 32
Study 8951261 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS-opportunistic infection group
Number of subjects: 32
Study 8951261 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected-other group
Number of subjects: 32
Study 8951261 — intervention group
Group type: COMPARATOR
Intervention: Reverter children
Number of subjects: 32
Study 8951261 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 32
Study 1837425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-anaesthetic dose of propofol
Number of subjects: 53
Study 1837425 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 53
Study 6353078 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis treatment
Number of subjects: 120
Study 6353078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no digitalis)
Number of subjects: 120
Study 31930894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (penetrating acupuncture + kinesiotherapy)
Number of subjects: 105
Study 31930894 — intervention group
Group type: COMPARATOR
Intervention: Penetrating acupuncture
Number of subjects: 105
Study 31930894 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy
Number of subjects: 105
Study 29306479 — intervention group
Group type: EXPERIMENTAL
Intervention: serelaxin
Number of subjects: 1161
Study 26892215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver oral health knowledge
Number of subjects: 992
Study 26892215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver oral health behavior
Number of subjects: 992
Study 26892215 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved caregiver behavior score
Number of subjects: 992
Study 25096386 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain antisepsis (chlorhexidine disc dressing and sodium hypochlorite irrigation)
Number of subjects: 202
Study 25096386 — intervention group
Group type: COMPARATOR
Intervention: Standard drain care (control)
Number of subjects: 202
Study 25096386 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonized sides (tubing or fluid)
Number of subjects: 202
Study 21632437 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy for Life Program (HELP) intervention
Number of subjects: 76
Study 20947884 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab 5μg/kg intravenously on days 1 and 2
Number of subjects: 127
Study 20947884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 18295692 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-iodized oil emulsions with nonionic contrast medium (experimental group)
Number of subjects: 197
Study 18295692 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-iodized oil emulsions with ionic contrast medium (control group)
Number of subjects: 197
Study 18295692 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of tumor grades between groups
Number of subjects: 197
Study 18295692 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient survival
Number of subjects: 197
Study 16499887 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg)
Number of subjects: 14
Study 16499887 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 14
Study 16499887 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 14
Study 16499887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14530475 — intervention group
Group type: COMPARATOR
Intervention: (123)I‐MIBG myocardial scintigraphy in group C
Number of subjects: 46
Study 14530475 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy in groups A, B, and C
Number of subjects: 46
Study 14530475 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy in group A
Number of subjects: 46
Study 14530475 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy in group B
Number of subjects: 46
Study 11052840 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 502
Study 11052840 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotablation
Number of subjects: 502
Study 8552791 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 8552791 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 1373033 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-designed note cards
Number of subjects: 0
Study 1373033 — intervention group
Group type: COMPARATOR
Intervention: Self-designed note cards
Number of subjects: 0
Study 6849275 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighed food intake recorded on tape recorders
Number of subjects: 18
Study 6849275 — intervention group
Group type: COMPARATOR
Intervention: Estimated food intake recorded in small notebooks
Number of subjects: 18
Study 6849275 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day dietary record (both methods)
Number of subjects: 18
Study 31912673 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and pegylated liposomal doxorubicin (CD)
Number of subjects: 432
Study 31912673 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 432
Study 30736376 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 36
Study 30736376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 28864865 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20
Study 28864865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25702958 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy protein (HP-D, >1.2 g of protein/kg body weight/d; ∼27 g/d dairy protein)
Number of subjects: 179
Study 25702958 — intervention group
Group type: EXPERIMENTAL
Intervention: High soy protein (HP-S, >1.2 g of protein/kg body weight/d; ∼27 g/d soy protein)
Number of subjects: 179
Study 25702958 — intervention group
Group type: COMPARATOR
Intervention: Usual protein intake (UP, <1.2 g of protein/kg body weight/d)
Number of subjects: 179
Study 23688276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospexin®
Number of subjects: 24
Study 23688276 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI Cephalexin® tablet
Number of subjects: 24
Study 23688276 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI Cephalexin® capsule
Number of subjects: 24
Study 22736448 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealant, single placement
Number of subjects: 501
Study 22736448 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF varnish, semi‐annual application
Number of subjects: 501
Study 22736448 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) solution, annual application
Number of subjects: 501
Study 22736448 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 501
Study 19648706 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE Program intervention
Number of subjects: 178
Study 19648706 — intervention group
Group type: COMPARATOR
Intervention: Standard public school curriculum
Number of subjects: 178
Study 17766015 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine
Number of subjects: 20
Study 17766015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15249261 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based online medical record (SPPARO software)
Number of subjects: 107
Study 15249261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to online medical record)
Number of subjects: 107
Study 11428472 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg at bedtime, increased to 20 mg if necessary) with behavioral modification
Number of subjects: 80
Study 11428472 — intervention group
Group type: COMPARATOR
Intervention: Behavioral modification alone (calorie control and daily walking for 30 minutes)
Number of subjects: 80
Study 9876998 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral administration of alpha-lipoic acid
Number of subjects: 12
Study 9876998 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral administration of alpha-lipoic acid
Number of subjects: 12
Study 9876998 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg intravenous administration of alpha-lipoic acid
Number of subjects: 12
Study 7986557 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily
Number of subjects: 100
Study 7986557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2786856 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine 900 mg/day for one month
Number of subjects: 24
Study 2786856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31928551 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐identified change agents (PICAs)
Number of subjects: 2
Study 31928551 — intervention group
Group type: COMPARATOR
Intervention: Management‐selected change agents (MSCAs)
Number of subjects: 2
Study 30789633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096
Study 30789633 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study 28275125 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS-LNS group (women and children both received LNSs)
Number of subjects: 4011
Study 26062124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-primed NK cells (TpNK) infusion
Number of subjects: 7
Study 23897401 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached EMS practice (2009)
Number of subjects: 16
Study 23897401 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple EMS practices
Number of subjects: 16
Study 23897401 — intervention group
Group type: EXPERIMENTAL
Intervention: Single EMS practices
Number of subjects: 16
Study 23897401 — intervention group
Group type: COMPARATOR
Intervention: Routine training (controls)
Number of subjects: 16
Study 20215489 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to Vigorous Physical Activity (MVPA)
Number of subjects: 380
Study 20215489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior (SED)
Number of subjects: 380
Study 20215489 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Class Time
Number of subjects: 380
Study 20215489 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving PA Guidelines
Number of subjects: 380
Study 20215489 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Education (PE)
Number of subjects: 380
Study 19842721 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (2000-U bolus + 500 U/h)
Number of subjects: 64
Study 19842721 — intervention group
Group type: COMPARATOR
Intervention: High-dose heparin (3000-U bolus + 800 U/h)
Number of subjects: 64
Study 17088511 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional-delivered home-visiting intervention
Number of subjects: 53
Study 17088511 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding education program (Control)
Number of subjects: 53
Study 15516040 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucerna SR
Number of subjects: 456
Study 15516040 — intervention group
Group type: COMPARATOR
Intervention: Resource Suport
Number of subjects: 456
Study 11894755 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil enriched diet
Number of subjects: 60
Study 11894755 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 60
Study 9756679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-technology lead hazard reduction activities (cleaning and repainting window areas, educating caregivers)
Number of subjects: 0
Study 9756679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-technology lead hazard reduction activities
Number of subjects: 0
Study 9756679 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with lesser hazards)
Number of subjects: 0
Study 7851099 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Teams (CTTs)
Number of subjects: 60
Study 7851099 — intervention group
Group type: COMPARATOR
Intervention: Intensive Case Management Teams (ICMTs)
Number of subjects: 60
Study 2898320 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg metaclazepam per day for 2 weeks
Number of subjects: 50
Study 2898320 — intervention group
Group type: COMPARATOR
Intervention: 4 mg bromazepam per day for 2 weeks
Number of subjects: 50
Study 29703031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy administered in the region of the parotid glands bilaterally and in the regions of the submandibular and sublingual glands
Number of subjects: 50
Study 28222379 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 0
Study 28222379 — intervention group
Group type: EXPERIMENTAL
Intervention: sORP >140mV
Number of subjects: 0
Study 28222379 — intervention group
Group type: EXPERIMENTAL
Intervention: cORP <0.50μC
Number of subjects: 0
Study 28222379 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sORP values
Number of subjects: 0
Study 28222379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cORP values
Number of subjects: 0
Study 25424454 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h 75 g OGTT using the IADPSG criteria
Number of subjects: 68
Study 25424454 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h 100 g OGTT using the Carpenter‐Coustan criteria
Number of subjects: 68
Study 25424454 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h 75 g OGTT or whichever test is recommended by their doctor
Number of subjects: 68
Study 25424454 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening endorsed by physicians and nurse midwives
Number of subjects: 68
Study 25424454 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded randomized GDM screening trial
Number of subjects: 68
Study 23190251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis group receiving three 1-hour lessons in self-hypnosis with additional audiorecordings
Number of subjects: 1222
Study 23190251 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group receiving three 1-hour lessons in various relaxation methods and mindfulness with audiorecordings
Number of subjects: 1222
Study 23190251 — intervention group
Group type: COMPARATOR
Intervention: Usual care group receiving ordinary antenatal care only
Number of subjects: 1222
Study 21593803 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg intravenously once daily for 2 weeks
Number of subjects: 22
Study 18477783 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300-mg loading dose followed by daily dose of 75 mg; n = 441)
Number of subjects: 877
Study 18477783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 436)
Number of subjects: 877
Study 16792608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic orotracheal intubation
Number of subjects: 60
Study 16792608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic nasotracheal intubation
Number of subjects: 60
Study 15849922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 456
Study 15849922 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 456
Study 12505224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin (pooled doses)
Number of subjects: 0
Study 12505224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin 10 mg
Number of subjects: 0
Study 12505224 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 80 mg alone
Number of subjects: 0
Study 12505224 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of ezetimibe and simvastatin
Number of subjects: 0
Study 12505224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin
Number of subjects: 0
Study 9623929 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets and curtains
Number of subjects: 0
Study 7792558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 22
Study 7792558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion with selective beta 1-blockade (Metoprolol)
Number of subjects: 22
Study 7792558 — intervention group
Group type: COMPARATOR
Intervention: Basal postoperative conditions
Number of subjects: 22
Study 7792558 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and lactate uptake
Number of subjects: 22
Study 2613867 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinsemination interval (PII) ranging from 30 to 540 minutes
Number of subjects: 1474
Study 11760 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high dose fluphenazine decanoate (250 mg weekly)
Number of subjects: 50
Study 11760 — intervention group
Group type: COMPARATOR
Intervention: Standard dose fluphenazine decanoate (12.5 mg weekly)
Number of subjects: 50
Study 30583032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 162
Study 30583032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 28574723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 12
Study 28574723 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 12
Study 25926252 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month pre-operative physical rehabilitation protocol
Number of subjects: 50
Study 25926252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical rehabilitation)
Number of subjects: 50
Study 23452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous community treatments for trichotillomania
Number of subjects: 62
Study 23452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Age progression in hairpulling behavior
Number of subjects: 62
Study 23452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in distress and impairment
Number of subjects: 62
Study 21478660 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 60
Study 21478660 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (closed treatment)
Number of subjects: 60
Study 18342398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Phe (10 g)
Number of subjects: 32
Study 18342398 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Phe (5 g Phe and 5 g glucose)
Number of subjects: 32
Study 18342398 — intervention group
Group type: COMPARATOR
Intervention: Control (10 g glucose)
Number of subjects: 32
Study 16575237 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of forced bathing
Number of subjects: 0
Study 16575237 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexpensive, practical, and evidence-based alternatives to forced bathing
Number of subjects: 0
Study 12614303 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, 40 mg once daily
Number of subjects: 5241
Study 12614303 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole, 30 mg once daily
Number of subjects: 5241
Study 11115698 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccine (1, 2, or 4 microg)
Number of subjects: 12
Study 9081208 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 0
Study 9081208 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (CC)
Number of subjects: 0
Study 8441910 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone, 7.5 mg/kg/day
Number of subjects: 133
Study 8441910 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol, 75 mg/kg/day
Number of subjects: 133